分红多募资少。 A股市场下起"红包雨"，现金分红成为主流。 根据Wind数据，截至8月21日收盘，已有160家上市公司披露了2025年中期分红预案，仅20日晚间就有 23家公告了分红预案。其中，牧原股份（002714.SZ）的分红计划受到市场关注，该公司拟每10股派发 现金红利9.32元，分红金额超过50亿元。 此前的8月19日晚间，吉比特（603444.SH）、福耀玻璃（600660.SH）公告，每10股拟派发现金红利分 别为6.6元、0.9元，拟派发现金4.74亿元、23.49亿元。这两只股票的共同点在于，上市以来的分红总额 已超过实际募资总额。 其中，福耀玻璃是分红融资比排名前十的公司之一。依据Wind数据计算，贵州茅台（600519.SH）、山 西汾酒（600809.SH）、宁沪高速（600377.SH）、兖矿能源（600188.SH）、五粮液（000858.SZ）、 达安基因（002030.SZ）、格力电器（000651.SZ）、江铃汽车（000550.SZ）、重庆啤酒（600132.SH） 是另外9家，前十大"分红王"的分红融资比均超过24倍。其中，贵州茅台分红融资比超150倍，这意味着 每募集1 ...

Core Viewpoint - The company, Da An Gene, indicated that specific financial data should be monitored through its regular reports and related announcements [2] Summary by Relevant Categories - **Company Financials** - Da An Gene responded to investor inquiries on August 15, emphasizing the importance of following its periodic reports for detailed financial information [2]

Core Viewpoint - Da An Gene has recently obtained a medical device registration certificate from the National Medical Products Administration for its human MTHFR gene typing detection kit, which is valid until August 13, 2030 [2]. Company Summary - The newly approved kit is designed for the qualitative detection of polymorphisms at the C677T site of the MTHFR gene in human whole blood genomic DNA [2].

Group 1 - The core point of the article is that Da An Gene has received a medical device registration certificate from the National Medical Products Administration for its "Human MTHFR Gene Typing Detection Kit" [2] - In the fiscal year 2024, Da An Gene's revenue composition is projected to be 96.2% from the biopharmaceutical sector and 3.8% from financial services [2]

Core Viewpoint - DaAn Gene has recently obtained a medical device registration certificate from the National Medical Products Administration for its human MTHFR gene typing detection kit, which is designed for in vitro qualitative detection of the MTHFR gene C677T polymorphism in human whole blood genomic DNA [1] Company Summary - The medical device is named "Human MTHFR Gene Typing Detection Kit (PCR-Fluorescent Probe Method)" [1] - The kit is applicable for the qualitative detection of the MTHFR gene C677T site polymorphism [1]

Core Viewpoint - The company, Da An Gene, has recently obtained a medical device registration certificate for its MTHFR gene typing detection kit, which enhances its product portfolio and expands application areas [1] Group 1 - The registration certificate was issued by the National Medical Products Administration, with the certificate number being 国械注准20253401571 [1] - The effective period of the registration certificate is from the date of approval until August 13, 2030 [1] - The kit is designed for in vitro qualitative detection of the polymorphism at the C677T site of the MTHFR gene in genomic DNA from human whole blood samples [1] Group 2 - The acquisition of this registration certificate enriches the company's product offerings [1] - The product is currently in the market development stage, indicating that market demand remains uncertain [1]

证券代码：002030 证券简称：达安基因 公告编号：2025-041 广州达安基因股份有限公司 关于取得一个医疗器械注册证的提示性公告 特此公告。 广州达安基因股份有限公司 董 事 会 2025 年 8 月 15 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督管 理局颁发的医疗器械注册证一个，具体为： 医疗器械名称：人类 MTHFR 基因分型检测试剂盒（PCR-荧光探针法），注 册证编号：国械注准 20253401571。有效期自批准之日起至 2030 年 8 月 13 日。 预期用途：本试剂盒适用于体外定性检测人全血样本基因组 DNA 中 5,10-亚甲基 四氢叶酸还原酶（MTHFR）基因 C677T 位点的多态性。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 ...

Group 1 - Multiple listed companies are developing detection solutions for Chikungunya virus, including Kingmed Diagnostics, Wanfu Biology, and Shengxiang Biology [1][2] - Kingmed Diagnostics has established a comprehensive platform for serological, fluorescent PCR, and sequencing tests to accurately identify the Chikungunya virus, aiding in clinical diagnosis [1] - Wanfu Biology has responded to the recent guidelines from the National Disease Control Bureau by developing several detection products that create a closed-loop system for rapid screening, precise detection, and monitoring [1] - Shengxiang Biology has introduced a dual-platform solution combining rapid nucleic acid testing and sequencing for precise tracing, with a detection time of 25 to 45 minutes and high sensitivity [1] Group 2 - According to a report by Everbright Securities, several domestic listed companies, including Da'an Gene, Wanfu Biology, Shengxiang Biology, Zhijiang Biology, Shuoshi Biology, Mingde Biology, and Rendu Biology, have launched Chikungunya virus detection solutions [2]

Core Viewpoint - The company, Da'an Gene, stated that as of July 31, 2025, the total number of shareholders is expected to be approximately 158,000 [1] Summary by Relevant Sections - Shareholder Information - The company anticipates having around 158,000 shareholders by the end of July 2025 [1]

Market Overview - The precision medicine sector experienced a decline of 1.18% on August 1, with WuXi AppTec leading the drop [1] - The Shanghai Composite Index closed at 3559.95, down 0.37%, while the Shenzhen Component Index closed at 10991.32, down 0.17% [1] Stock Performance - Notable gainers in the precision medicine sector included: - Ruian Gene (688217) with a closing price of 30.34, up 5.38% [1] - Da An Gene (002030) at 7.18, up 3.01% [1] - New Open Source (300109) at 17.03, up 2.34% [1] - Conversely, major decliners included: - WuXi AppTec (603259) at 93.00, down 3.40% [2] - Anke Bio (300009) at 11.90, down 1.73% [2] - Zhongyuan Union (600645) at 26.10, down 1.51% [2] Capital Flow - The precision medicine sector saw a net outflow of 993 million yuan from institutional investors, while retail investors contributed a net inflow of 668 million yuan [2][3] - The capital flow for specific stocks showed: - Da An Gene (002030) had a net inflow of 46.97 million yuan from institutional investors [3] - WuXi AppTec (603259) experienced a net outflow of 83.98 million yuan [2][3]